Lung Cancer | Specialty

Treatment Options for mNSCLC After Progression

February 26th 2019

CheckMate-227 and the Role of TMB in NSCLC

February 26th 2019

Looking at the IMpower Data in NSCLC

February 26th 2019

Choosing Therapy for Newly Diagnosed NonDriver NSCLC

February 26th 2019

Driver Mutations Trump PD-L1 Expression in Lung Adenocarcinoma

February 26th 2019

Biomarker Testing in Stage III NSCLC

February 26th 2019

Imaging Schedule Following CRT in Locally Advanced NSCLC

February 26th 2019

The Role of Surgery in NSCLC Following PACIFIC Trial

February 26th 2019

Impact of PACIFIC Trial on Locally Advanced NSCLC

February 26th 2019

Dr. Cerfolio on the Role of Surgery in Lung Cancer

February 26th 2019

Robert J. Cerfolio, MD, director of the Lung Cancer Center, chief of clinical thoracic surgery, NYU Langone’s Perlmutter Cancer Center, discusses the role of surgery in lung cancer.

Dr. Subramanian Discusses Tumor Biology in Lung Cancer

February 23rd 2019

Janakiraman Subramanian, MD, a medical oncologist and director of thoracic oncology and director of the Center for Precision Medicine at Saint Luke’s Cancer Institute, discusses tumor biology in lung cancer.

Dr. Socinski on Current State of Treatment in NSCLC

February 22nd 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses the current state of treatment for patients with non–small cell lung cancer.

Dr. Goldberg on Managing CNS Metastases in Oncogene-Driven NSCLC

February 21st 2019

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses strategies for managing central nervous system metastases in patients with oncogene-driven non–small cell lung cancer.

FDA Grants Pembrolizumab Priority Review for Advanced SCLC

February 20th 2019

The FDA has granted a priority review designation to a supplemental biologics license application for pembrolizumab (Keytruda) as a treatment for patients with advanced small cell lung cancer whose disease has progressed following ≥2 prior lines of therapy.

FDA Grants Entrectinib Priority Review for NTRK+ Tumors and ROS1+ NSCLC

February 20th 2019

The FDA has granted a priority review designation to a new drug application for entrectinib as a treatment for select adult and pediatric patients with NTRK fusion–positive locally advanced or metastatic solid tumors, as well as patients with metastatic ROS1-positive non–small cell lung cancer.

Dr. Shum on Mechanisms of Resistance in Oncogene-Driven NSCLC

February 19th 2019

Elaine Shum, MD, medical oncologist, NYU Langone’s Perlmutter Cancer Center, discusses mechanisms of resistance in patients with oncogene-driven non–small cell lung cancer (NSCLC).

Dr. Davis on Comparisons Between Robotic Surgery and Open Surgery in Lung Cancer

February 19th 2019

J. Russell Davis, MD, clinical professor, University of Missouri–Kansas City School of Medicine, thoracic surgeon, Saint Luke's Hospital, compares the use of robotic surgery with open surgery in patients with lung cancer.

Multimodality Approach Best for CNS Disease in NSCLC

February 18th 2019

Sarah B. Goldberg, MD, MPH, sheds light on the complex treatment paradigm for patients with lung cancer who have central nervous system metastases and highlights emerging treatment strategies for those with mesothelioma.

Dr. Drilon on Rare Drivers in NSCLC

February 15th 2019

Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering (MSK) Cancer Center, discusses rare drivers in non–small cell lung cancer (NSCLC).

Brahmer Calls for Better Incorporation of Precision Medicine in Lung Cancer

February 14th 2019

Julie R. Brahmer, MD, discusses advances made with immunotherapy in the lung cancer space, highlights challenges that still need to be addressed, and sheds light on ongoing research designed to determine treatment approaches beyond PD-1/PD-L1 and CTLA-4 inhibition